Janux Therapeutics (NASDAQ:JANX) rose 7% amid some renewed takeover speculation. Merck (MRK) is rumored to be one of the parties involved in the Janux (JANX) strategic alternatives review, according ...
Source LinkJanux Therapeutics (NASDAQ:JANX) rose 7% amid some renewed takeover speculation. Merck (MRK) is rumored to be one of the parties involved in the Janux (JANX) strategic alternatives review, according ...
Source Link
Comments